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Studies of absorption, distribution, metabolism, and elimination (ADME) have long been recognized as important in the evaluation of the pharmaco-
logical efficacy of pharmaceutical agents. In recent years, the importance of ADME studies in toxicology also has become increasingly apparent. In
realization of the importance of ADME studies, regulatory agencies have established guidelines governing the conduct of these studies. To be of
maximum utility, it is desirable that ADME and pharmacokinetic studies be closely integrated with the toxicity testing protocol. However, in many
instances this is not the case, which results in ADME and pharmacokinetic studies that are often chronologically and philosophically remote from
the toxicity testing protocols. An inevitable consequence of this approach is that it frequently leads to the generation of ADME data that are of lim-
ited use in the process of toxicity evaluation and risk assessment. Recently, there has been increased focus on developing testing strategies that
would result in the development of ADME data with greater application to toxicity testing and risk assessment. An example of such an approach is
the concept of a tiered approach to the conduct of ADME studies. An important aspect of the tiered approach is generating ADME data at an earlier
stage during the toxicity testing of a chemical. This could be effected by acceptance of the concept of a minimum experimental data set for a chemi-
cal. This minimum data set could be conducted in a timely and economic manner and would develop data addressing three fundamental questions:
Is the chemical absorbed? Is the chemical metabolized? Does the chemical persist? The data generated under a minimum data set scenario would
not be designed to provide sufficient information for utility in risk evaluation. However, it would provide important information at a much earlier stage
of toxicity testing than currently generated under existing testing strategies. Such information would be of importance in the design of toxicity test-
ing studies. Additional ADME and pharmacokinetic information could then be conducted when a specific concern (e.g., toxicity) becomes apparent.
The advantage of this approach is that it allows the design of these additional follow-up studies to be tailored to the particular toxicity or risk-evalua-
tion end point (e.g., target organ, species extrapolation, route evaluation, etc.). The specifics of the experimental aspects of the design of ADME and
pharmacokinetics studies are discussed. In this development of alternate, and more efficient procedures, for the conduct of metabolism studies, it
has become apparent that the potential use of ADME data obtained under studies designated by the regulatory guidelines is often of little use in
addressing the major concerns of risk assessment (i.e., species, dose, and route extrapolation). In considering alternate approaches it has become
apparent that increased use of dosimetry models such as physiologically based pharmacokinetic models could have significant utility in improving
the risk assessment procedure. In recent years there has been growing support for the pharmacokinetic modeling approaches and, in particular,
physiologically based pharmacokinetic (PBPK) models have been increasingly used in risk assessment by providing a unified description of the
dynamics of chemicals and their metabolites in the blood, specific tissues and excreta. In addition to providing a dosimetric of the relationship
between the exposed concentration and tissue dose, these models can also be linked to so-called biologically based dose-response models. These
latter models are being developed to incorporate information on our understanding of toxicological mechanisms. Such models, in conjunction with
PBPK models provide an improved biological basis for examining the relationship between chemical exposure and effect. The advent of these models
heralds the prospect of reducing the uncertainty in the risk assessment process. - Environ Health Perspect 102(Suppl 11):5-1 1 (1994)
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Introduction
Studies ofthe metabolism and pharmacoki-
netics ofchemicals are recognized as critical
elements in the safety evaluation of chemi-
cals (1). Regulatory guidelines for the con-
duct of metabolism and pharmacokinetic
studies exist under the U.S. Environmental
Protection Agency (U.S. EPA [FIFRA]),
Food and Drug Administration (FDA), the
Organization for Economic Cooperation
and Development (OECD), the European
Economic Community (EEC) and in
This paper was presented at the Workshop on
Pharmacokinetics: Defining Dosimetry for Risk
Assessment held 4-5 March 1992 at the National
Academy of Sciences in Washington, DC.
Address correspondence to Dr. A.G. Wilson,
Monsanto Company, St. Louis, MO 63110.
Telephone (314) 694-8818. Fax (314) 694-4028.
Japan. Metabolic and pharmacokinetic
studies conducted on specific chemicals
which fall under the jurisdiction ofthe EPA
are typically addressed in EPA/TSCA
(Section 4) Test Rules for the respective
chemical and EPA/FIFRA testing for pesti-
cide registration. Recently, the Office of
Toxic Substances ofthe EPA issued a pro-
posed generic draft guideline for the conduct
ofmetabolism and pharmacokinetic studies.
Prior to the issuance ofthis guideline, a
number ofchemical companies had formed
an association (The Pharmacokinetics
Group) under the auspices ofthe Synthetic
Organic Chemical Manufacturers Asso-
ciation (SOCMA). The purpose of this
SOCMA Pharmacokinetics (PK) Group
was to provide a discussio;n forum for
approaches to the study ofthe pharmacoki-
netics and metabolism ofchemicals and the
application ofthis data in safety evaluation.
The SOCMA PK Group strongly supported
the incorporation ofPK and metabolic con-
siderations into the risk assessment process
and the need for a pharmacokinetic guide-
line under TSCA. The SOCMA PK Group,
however, was concerned that flexibility be
incorporated into any proposed guideline
since there is an implicit need for PK
studies to be tailored to the specific chemi-
cal, its proposed use, and route ofpotential
human exposure. In addition, the SOCMA
PK Group hoped that harmonization of
the proposed TSCA guideline with other
metabolism and PK guidelines would be
possible. Recent TSCA section 4 test rules
had raised concern that much of the PK
data requested by the EPA was not tailored
to the proposed use of the chemical and,
therefore, was not ofmaximal utility in risk
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assessment. Following discussion with the
EPA about these concerns, it was decided to
convene a workshop that would provide a
dialogue on the design and conduct ofphar-
macokinetic studies and to reach clarification
and agreement on technical issues regarding
the design ofpharmacokinetic studies.
The Pharmacokinetics Workshop was
organized by the Office ofToxic Substances
(OTS) and the SOCMA Pharmacokinetics
Group. The workshop was held at the Key
Bridge Marriott, Washington, DC, on
March 7 and 8, 1990. Over 50 experts in
various aspects ofmetabolism and pharma-
cokinetic studies participated.
Following introductory remarks from
L. Tahan (U.S. EPA, OTS), R. Zendzian
(U.S. EPA, OPP), andA. Wilson (Monsanto
Company) and SOCMA Pharmacokinetics
Group) attendees participated in focused
breakout sessions that covered the follow-
ing topics: minimum data set require-
ments, conduct ofdermal pharmacokinetic
studies, conduct of inhalation route phar-
macokinetic studies, conduct ofpharmaco-
kinetic studies by oral and other routes,
consideration ofdose and animal selection,
metabolite identification and characteriza-




Metabolism and PK studies are often
chronologically and philosophically remote
from the toxicity testing protocols. The lack
ofcorrelation between the two types oftests
significantly affects the utility of metabo-
lism and PK information in safety assess-
ment. To be ofmaximal utility, metabolism
and PK studies must be integrated with the
toxicity studies for the particular chemical
and must be targeted to a toxicologic end
point. Under the present TSCA section 4
test rules, this is rarely possible because
metabolism and PK studies are typically
conducted consecutively with toxicity stud-
ies. Therefore, potential target sites for toxi-
city are generally not known at the time the
metabolism and PKstudies are conducted.
The drawback to this approach is that
in the event oftoxicity the metabolism and
PK studies would frequently be oflittle use
in addressing the toxicity concern. In the
event ofa toxic response, additional meta-
bolic studies typically would be needed to
develop data that would have a greater
probability ofaddressing any safety con-
cerns ofthe chemical. To address the ques-
tion ofmore closely integrating metabolism
and PK studies with the toxicity testing
and the risk assessment of a chemical, the
Table 1. Pharmacokinetic guideline decision tree.
Tier 1 Minimum data set




Tier 3 Metabolite characterization
Additional studies (e.g., binding studies;
species, sex, strain, and age considerations)
Other Pharmacokinetic modeling
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Figure 1. Pharmacokinetic decision tree-overview.
concept ofa decision tree approach for the
conduct ofmetabolism and PK studies was
developed. The basic outline ofthis tiered
approach is presented. Initial studies (tier 1
or minimum data set) could provide the
basis for decisions concerning the need for
additional pharmacokinetics studies. If
required (pharmacokinetic or toxicologic
considerations), then additional studies
(tier 2 and 3) would provide data useful in
risk assessment.
Minimum DataSet (Tier 1)
An essential component of this tiered
approach is the concept ofa minimum data
set. The specific components of the mini-
mum data set are outlined in the following
section. It was recognized by the group that
this minimum data set would not, in many
cases, be sufficient to assist in the design of
toxicity studies or interpretation oftoxicity
data. Rather the concept for the minimum
data set (tier 1) was conceived as being the
minimum that would be acceptable for
assessing critical elementary characteristics
of the chemical, and would provide the
basic information for decisions concerning
the need for additional pharmacokinetic
studies. The minimum data set constitutes
tier 1 ofa three-tier system (Table 1, Figure
1). The specific study requirements for the
minimum data set are outlined below.
The Work Group agreed that the mini-
mum data set requirement (tier 1) would
ask three fundamental questions: Is the
chemical absorbed? Is the chemical metab-
olized? Does the chemical persist? These
questions are outlined as follows and dis-
cussed in detail below.
* Is the chemical absorbed?
Suggested: iv/additional route
excreta and/or blood
* Is the chemical metabolized?
Suggested: separation ofparent from
metabolites (e.g., excreta,
blood)




The study should be conducted using the
iv and an additional route. The additional
route can be the oral or the most likely
route of human exposure. This study
would in most cases be conducted using
radiolabeled material, although a nonradio-
labeled material would be acceptable pro-
viding a sufficiently sensitive analytic
procedure exists. The extent ofabsorption
could be determined by any acceptable and
validated procedure, for example:
Measurement ofthe Levels ofRadio-
activityin Urine orExpiredAir. Iffeces are
to be used to measure absorption, then
verification that the material present in the
feces is either a metabolite or that the parent
chemical can be absorbed and excreted
unchanged must be demonstrated.
Determination ofRadioactivity in
Blood Samples. Blood samples should be
collected at sufficient time intervals to per-
mit estimates of extent ofabsorption and
time course ofelimination from the blood
area under the blood concentration and
time curve.
Isthe ChemicalMetabolized?
To determine whether a chemical is metab-
olized, it would be required to analytically
demonstrate whether the material analyzed
was parent or metabolite(s). It is not, how-
ever, required at the tier 1 stage to charac-
terize or identify metabolites. It is forseen
that a characterized separation system, capa-
ble ofdistinguishing parent material from
metabolites, would would be sufficient to
answer the question. The matrix for analysis
would be flexible but would in most cases
include excreta or blood.
Does the ChemicalPersist.?
An assessment ofthe potential for the chem-
ical or its metabolites to persist in the body
is highly recommended. Determination of
whole body elimination would be sufficient
and could be determined using excreta data.
Direct tissue or blood analysis could also be
used to address the persistence ofa chemi-
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cal. Examples of kinetic parameters that
would relate to persistence would be half-life
(t1/2) of elimination or percent of dose
remaining in the body at a given time point
after dosing. The 90% eliminated or 7-day
postdosing time point was generally consid-
ered appropriate.
Minimum Experimental
Design forTler 1 Studies
A minimally experimental design was
developed for tier 1 studies.
* 3 animals per dose level
* 3 dose level
* 3 sex, male preferred
* Healthy young adults, matched for age
and bodyweight
* Rat preferred, unless other species used
in toxicity study
* 7 days or until 90% eliminated
* Relevant route, plus iv (absorption
determination)
It was recognized that in most cases the
same experiment or experimental design
would suffice to answer all three questions
posed in tier 1. The minimally acceptable
design for a tier 1 study was a) three ani-
mals per dose level; b) one dose level
(When possible, this dose level would be
equal to that used for iv study.); c) one sex
with preference given to the male; and d)
animals should be healthy young adults
matched for age and body weight. (In gen-
eral, it is recommended that animals
should not be less than 8 weeks ofage and
would preferably be 10 to 12 weeks ofage).
The preferred species is the rat unless
different from the species to be used in toxi-
city studies, then the latter would be the
species of choice. No a priori restrictions
were placed on the dose level to be used in
the iv study; however, it was recognized that
solubility and toxicity considerations might
be limiting. Time for collection ofexcreta
and blood samples would depend on the
individual chemical, but should span a
sufficient time period to permit accurate
determination ofextent ofabsorption. The
criteria of90% eliminated or 7 days were
viewed as appropriate to terminate collection.
Factors InfluencingNeedto
Do Morethan Minimum DataSet
Pharmacokinetic evaluations, in addition to
those obtained under the minimum data set
(tier 1), will be required in many cases. The
factors that should be considered to trigger
metabolism and PKstudies inaddition to that
obtained by the minimum data set studies are
outlinedbelow:
* Pharmacokinetic data needed for toxicity
studydesign or interpretation
* Exposure consideration
* Significant findings in tier 1 (i.e.,
absorption, metabolism, persistence)
No consensus was reached in this work-
shop for a quantitative evaluation ofwhat
constitutes a significant finding. However,
for the minimum data set, the level would
typically be assessed to be significant
absorption, metabolism, or persistence. It is
recognized that minimal levels ofabsorp-
tion could be of toxicological concern. In
this case, the need for additional pharma-
cokinetic studies would be triggered by the
toxicity data.
Tler2 Studies
The following were some general views of
the Work Group on the aspects to be con-
sidered under tier 2 studies. The studies
delineated by the other Work Groups
(Appendices I-V) describe the specific
components in greater detail.
Kinetics andDoseResponse
This study would monitor parent material
or dose surrogate. The prime objective of
this study would be to determine possible
nonlinearities in kinetics ofabsorption, dis-
tribution, metabolism, and elimination.
The proposed number ofdose levels would
be three with the dose range spanning a
minimum of two orders of magnitude
where possible. The low dose would be
equivalent to the human exposure level or
the dose level used in the intravenous study,
while the high dose should be related to the
LD50 (e.g., 1/10 LD50).The medium dose
should be appropriately placed between the
high- and low-dose groups.
Repeated (Multiple) Dosing
The question addressed here is: Does the
pharmacokinetics of the chemical change
upon repeated (multiple) dosing? The rec-
ommended procedure is a 7- to 14-day
repeat dosing with unlabeled material fol-
lowed by a single dose of radioactive sub-
stance. The Work Group considered a 7-day
predose period sufficient and in many cases
5 days would suffice. The Work Group also
supported the view that these repeat dosing
studies could be coupled with ongoing toxi-
city studies, in which case animals would be
administered trace levels of radioactive
material at specified intervals after study ini-
tiation. Typically, the animals would be a
satellite group in addition to those used in
the standard toxicitystudies.
Routes ofExposure
The effect of route of exposure can be
delineated at any time and would be con-
ducted in a manner consistent with that
outlined by the consensus reached by the
individual Work Groups addressing the
relevant route ofexposure.
Tier3 Studies
The studies outlined in this tier would gen-
erally be initiated as the result of toxicity
considerations or specific exposure ques-
tions. Some ofthe areas that would be con-
sidered in this tier are:
Metabolite Characterization. One of
the prime objectives ofmetabolism studies is
to relate information on metabolic biotrans-
formation to toxicity. To fulfill this end
point, it was not considered necessary to pro-
vide detailed characterization or identification
ofmetabolites or metabolic pathways unless
this is deemed necessary to address the
specific toxicologic concerns; considerable
flexibility was stressed in ensuring that the
metabolite analysis be tailored to the issue of
concern.
OtherApproaches. The Work Group
listed several other factors and end points
that may be applied to a specific toxicologic
concern: a) DNA and protein binding; b)
species, sex, strain, and age considerations;
c) human data; and ad) effect of formula-
tions and vehicles. The Work Group did
not spend any further time outlining these
since they would depend on the specific
toxicologic problem.
Pharmacokinetic Modeling. The Work
Group strongly endorsed the development
and application of physiologically based
pharmacokinetic (PBPK) modeling. They
felt that this technology was advancing at a
rate.where it will in the foreseeable future
play a significant role in both the prospec-
tive design of toxicity studies and retro-
spective analysis oftoxicity data. The Work
Group encourages the U.S. EPA to use
wording in the Pharmacokinetics Guide-
lines that would endorse the development
and utilization ofthis technology by indus-
try to support regulatory compliance.
Furthermore, the group endorsed the view
that scientifically validated PBPK modeling
could be used to augment the more stan-
dard pharmacokinetic approaches.
Appendices
Presented in the following Appendices are
the specific experimental designs to cover
studies in tier 2 and 3 ofthe decision tree.
These experimental designs stand alone
and are not part of the minimum data set
experiment protocol.
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Appendix I: DoseandAnimal Selection
Dose Selection. The participants addressed
the following issues with regard to dose
and animal selection in PKstudies:
a) What factors influence the selection
ofdosage routes?
Primary consideration should be given
to the route of human exposure to the
chemical, and that this exposure route
should be reproduced in the PK investiga-
tion. When PK studies are designed to aid
in the interpretation ofan existing or antic-
ipated toxicity study, then the exposure
route used in that study should also be
used for the PK study. While both toxicity
and PK studies are conducted ideally by
the environmentally relevant route, this is
not always done in chronic and subchronic
studies because ofpractical considerations.
To enable route-to-route comparisons, the
PK study should ideally be performed by
both the relevant route and by the route
used in the toxicity study. When such
comparisons are to be made, however, an
appropriate dose surrogate must be
identified for use in making comparisons,
such as the area under the curve (AUC) of
the parent compound in blood. It was rec-
ognized that this approach goes beyond the
minimum approach. A probe study con-
ducted by the oral gavage route, for exam-
ple, may be useful for obtaining large
quantities ofmetabolites to aid in metabo-
lite identification. The iv route ofadminis-
tration is generally useful as a comparison
route for generating PK parameter esti-
mates in the absence ofabsorption consid-
erations, but it is recognized that solubility
ofthe test chemical in aqueous media and
local injection effects (e.g., sclerosis) may
preclude the iv route for some chemicals.
b) How many dose levels are necessary
for PK studies by the iv, oral, dermal, and
inhalation routes?
One dose level is generally sufficient for
i.v. studies. For studies where the question
of nonlinear dose effects are to be
addressed, two or three dose levels should
be used. Ifthe PK study is designed to help
set dose levels for a toxicity study, then a
minimum of three dose levels should be
used. If, on the other hand, the PK study is
being conducted to help interpret data
obtained from a toxicity study, then two
doses set at the low- and high-dose levels
used for the toxicity study may be
sufficient. Because the dermal route of
exposure often results in relatively low
blood levels oftest compound, nonlinearity
may be better determined using the oral or
inhalation routes. Therefore, one dose level
may be sufficient for dermal studies
depending upon the aim of the investiga-
tion. Additional dose levels in dermal stud-
ies may yield useful information if the
chemical is rapidly absorbed or metabo-
lized by the skin.
c) What criteria should be used in set-
ting dose levels for iv, oral, inhalation, and
dermal studies?
Doses selected should not induce toxic-
ity upon a single administration. The high-
est dose may be selected to produce
minimal toxic effects upon repeated
administration, and may, therefore, be
equivalent to the mean therapeutic dose of
a chronic or subchronic study. The lower
dose(s) should typically be 10- to 100-fold
lower than the high dose to discriminate
first-order (linear) pharmacokinetic pat-
terns. Doses (i.e., concentrations) for vapor
inhalation studies should not exceed 50%
of the lower explosive limit. In aerosol
inhalation studies, doses that significantly
overload pulmonary clearance should be
avoided. In dermal studies, doses selected
will depend on the protocol followed (i.e.,
finite versus infinite dosing) and the
specific aims ofthe investigation.
In the finite dose protocol, a limited
amount ofchemical is applied to the skin
and the percent absorbed is determined. In
the infinite dose protocol, a large excess of
chemical is applied to the skin so that the
concentration ofchemical at the skin sur-
face is very high (i.e., essentially infinite)
during the course of the experiment. The
maximum feasible dermal dose is a useful
approach for obtaining absorption rate
information for-many chemicals. However,
ifthe chemical produces excessive irritation
or ulceration upon dermal exposure to high
concentrations, then more dilute solutions
should be used. The surface area ofexpo-
sure used in dermal studies should always
be specified.
d) How is the effect of repeated
(multiple) administration on PK and
metabolism best studied?
Repeated administration (at least 7 con-
secutive days) of unlabeled test chemical
followed by administration ofradiolabeled
test chemical is a common approach for
examining the effect ofenzyme induction
or inhibition on the metabolic pattern and
kinetic profile. Bioaccumulation, on the
other hand, is not addressed by this
approach but may be predicted by model-
ing the data from a single administration.
Repeated dermal PK studies are generally
not recommended because there are no
widely accepted procedures for repetitive
application, containment, and recovery of
chemicals by the dermal route. The ques-
tion of enzyme induction by dermally
applied chemicals may be addressed by
other approaches, such as the direct deter-
mination of enzyme levels after repeated
application. The development of methods
for repetitive dermal PK studies was recom-
mended as an area needing further research.
e) What radiochemical purity is feasible
and sufficient for a meaningful study?
The difficulties encountered in attain-
ing highly pure radiochemicals were dis-
cussed. The recommendation was made
that compounds should be 95 to 99%
radiochemically pure and that any 2% and
greater impurity should be chemically
identified (e.g., by comparison ofretention
time with known standards).
AnimalSelection. The following issues
are pertinent questions regarding the
appropriate selection of the test species to
be used in PK studies:
a) What factors influence the selection
oftest species and strain?
The rat is the species ofchoice for PK
studies. Additional or alternate species may
be selected if there is a specific need. The
selection of rat strain should be guided by
the strain used in chronic or subchronic
toxicity investigations.
b) What factors influence the age selec-
tion ofanimals?
The age of the experimental animals
must be consistent (e.g., + 1 week) within
each PK experiment. The sexually mature
adult is generally the animal of choice;
however, depending on the study objec-
tives, older animals may be preferable. Ifit
is necessary to obtain serial blood samples,
consideration should be given to the size
of the animals so that the overall volume
of blood withdrawn does not adversely
affect the health of the animals or the
pharmacokinetic parameters (e.g., < 10%
ofthe bloodvolume).
c) When should PK studies be con-
ducted on both sexes?
It was recommended that one sex gen-
erally be used, males preferred. Females
should be used when indicated by use or
exposure data. Both sexes should be used




Definitions. To establish consistent refer-
encing for commonly used terminology in
the analysis for test material and metabo-
lites, the following definitions were agreed
upon: Metabolite identification is defined
as the elucidation of chemical structure.
Metabolite characterization is defined as
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determination ofchemical or physical prop-
erties or both ofa metabolite and is distinct
from structure elucidation. Metabolite
profiling is defined as chromatographic sep-
aration that is of suffcient resolution to
determine chromatographically separable
components arising from the test substance,
induding unchanged test material.
Biologic Media for Metabolite
Charaeterization. Data from the intra-
venous and additional routes should guide
selection ofbiologic media for use in meta-
bolic characterization studies (i.e., mini-
mum data set). The following general
guidelines should be employed: Urinary
metabolites should be profiled when uri-
nary elimination is significant. Test mater-
ial, or metabolites, in expired air should be
characterized whenever present in
signficant amounts. Fecal metabolites
should be characterized when this is a
major route of elimination (.10% of
absorbed dose). Bile metabolites serve
equally well for characterization and may
have identification advantages over fecal
samples. Determination that feces is a major
route of excretion following absorption
would come from the iv study or from bile
cannulation studies. Blood is not generally
recommended as a media for routine
metabolite characterization unless knowl-




and timing of metabolite characterization
were: As a general rule, chromatographic
profiling should be conducted on a daily
basis from pooled (by dose level, route of
administration and sex) excreta samples
until the daily output (per pooled sample)
is less than about 10% ofthe administered
dose. Total radioactivity in each individual
sample also should be determined.
Various criteria for pooling ofsamples
from animals were recognized as having
value. Clear preference for any one proce-
dure was not found. As guidance, one
should use equal percentages ofexcretory
output from each animal by either a mass,
volume, or radioactivity basis. Random
pooling is to be avoided. Further characteri-
zation should be considered for any chro-
matographically separable metabolite that
exceeds, in toto, about 5% ofthe adminis-
tered dose, regardless of route ofexcretion
biologic media, sex, or dose level. An
important exception to this 5% rule is
where it is suspected that a metabolite at a
lower level is responsible for the toxic effects
ofa chemical. In such cases attempts should
be made to characterize this metabolite and
should be limited only by the sensitivity of
the analytic methodology. It is recom-
mended that this further characterization
should at least include an indirect character-
ization method such as enzymatic or acid
hydrolysis applied to a pooled sample. It is
further suggested that positive controls be
used for enzymatic procedures such as
,B-glucuronidase/sulfatase.
Test Material. It is strongly recom-
mended that radiolabeled test material be
used for the majority of these studies.
Unlabeled material can be used provided it
is documented that its use is consistent
with fulfilling the objectives ofthe studies.
This documentation should typically
include validation of extraction and ana-
lytic methods for tissues and excreta. The
position ofthe radiolabel in the test mole-
cule should be selected based on the least
vulnerable moiety for metabolic change
(e.g., on the core of the molecule) and
should be consistent with achieving the
objectives ofthe studies. In some circum-
stances, it will be necessary to use a test
material with the label in a second position
or one that includes a second type oflabel.
General labeling with tritium is not recom-
mended because of the possibility oflabel
exchange. The label position in the test
substance should be documented in the
study records.
Appendix III: Oral andOther Routes
GeneralDiseussion. The exposure routes
considered included intravenous (bolus and
infusion), oral (gavage, feeding, and drink-
ing water), intradermal/subcutaneous,
intraperitoneal, ocular, and intratracheal.
In addition to dosing routes, there was also
discussion on the purity of test material,
which gender to use, number ofanimals,
fasted versus nonfasted animals, animal
species, dose volumes, and treatment of
data. The group concluded that only oral
gavage (po) and bolus intravenous (iv) dos-
ing needed discussion. The other routes
were considered applicable only under spe-
cial circumstances.
The group agreed that the rat should be
the primary species, with alternative species
being considered based upon available data.
Rats should be fasted before dosing, in
order to have the amount of food in the
gastrointestinal (GI) tract at the same level
in all animals. In general, the test material
was considered to contain a radiochemical
label. The position ofthe label must be in a
location to accomplish the overall goals of
the study; labels in more than one position
may be required. Intravenous dosing exper-
iments were considered critical and were
called "guide-post" studies. Lack ofstabil-
ity in saline or water does not exclude iv
dosing apriorivery small amounts ofundi-
luted, high-specific activity test material
dosed intravenously can provide very
important information on overall rates and
routes ofelimination. A minimum ofone
dose level is required. The dose volume
should be kept under 1 ml/kg, must be
compatible with the biologic system, and
should not produce any overt signs oftoxi-
city. It is recognized that the nature ofthe
test material may exclude the iv dosing
route.
Study Design Considerations. Samples
collected include blood (plasma, serum),
urine, feces, and expired gases. Blood sam-
pling should continue through 72 hr post-
dose, and excreta should be collected
through 7 days; the study may be stopped
earlier if 90% or more of the dose can be
accounted for. Blood sampling volumes
and techniques should not compromise the
health of the animals. It was recognized
that different animals might be used for
bleeding and excreta collection. The car-
casses of animals used for excreta collec-
tions should be used for material balance
calculations. No evaluation of individual
organs is recommended. The group felt that
data from three animals per sex should be
presented. In the general session, several
other groups had decided that only data
from males were needed unless there were
toxicity data that indicated a possible sex
difference.
Data based on total radioactivity in the
urine, feces, and expired gases are indicators
of the important routes ofelimination of
systemic test material, and these should be
used to determine the general rates ofelimi-
nation. Total radioactive measurements in
the blood (plasma) or excreta can be used to
estimate elimination rates. All blood
(plasma) pharmacokinetic calculations
based on total radioactivity are limited and
must not be overinterpreted. Investigators
are encouraged to assay the blood (plasma)
samples for parent test material.
With the basic data from the guide-post
study available, an appropriately designed
oral study can be conducted. Pilot studies
can be useful for further refining the design
of definitive gavage studies. Gavage was
recommended as the preferred route oforal
exposure. Because of the complications
involved, administration through food or
drinking water should only be used to
answer specific questions, such as the effect
of food interactions on bioavailability.
Encapsulation of the test material may be
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acceptable if the encapsulation does not
prevent absorption.
The gavage study should include single-
dose studies (a low- and a high-dose) and a
multiple dose study. The low single dose
would mimic a dose that a human might
consume in the water or diet; it should not
produce signs of toxicity. The highest sin-
gle dose should be determined according to
three criteria: a) does not exceed 1000
mg/kg, b) can be administered in a volume
of5 ml/kg or less, and c) produces minimal
or no toxicity. The multiple-dose study
should be conducted using the dose level
used for the single low-dose study.
Additional Considerations. Depending
on the study objectives fasted or nonfasted
animals may be used. The study should
include measurements oftest material and
metabolites (when appropriate) in blood
and excreta. If excretion represents greater
than 95% ofthe administered dose, there is
no reason to suspect that the substance is
accumulating in a particular tissue or organ.
Under such situations, determination oftis-
sue distribution may not be necessary.
When tissue distribution is determined, it
should indude the major metabolic organs:
liver, kidney, brain, fat, bone, thyroid, mus-
cle, heart, GI tract, gonads, known targets
organs, and residual carcass.
The multiple dosing study should be
done over a period of at least 7 days. The
animals should be given nonradiolabeled
doses until they receive the final dose,
which should be radiolabeled. These ani-
mals may be fasted before receiving this
final dose, if preferred. Measurements
should include blood and excreta concen-
trations of test material and material bal-
ance. The observation period should be
determined according to the single-dose
group data.
The vehicle used for delivery of the
radiochemical should not interfere with
normal metabolism. The preferred vehicle
is saline; the second choice is an aqueous
suspension. The third choice, which should
only be used when other vehicles are not
practical, is a nonpolar solvent, such as
corn oil. The group recognized that corn
oil causes undesirable metabolic effects, but
could not identify an acceptable alternative
in all cases.
Append IV: Dermal Route
Phannacokinetics Studies
Study Design Considerations. The follow-
ing questions regarding the general design
considerations for a dermal pharmacokinet-
ics studywere discussed:
a) Should vehicles be used versus neat
applications?
Whenever possible, compounds should
be applied in vehicles that represent actual
human exposure conditions, (i.e., field
experience). Ideally, a vehicle should nei-
ther impair nor enhance absorption of a
compound, should not change concentra-
tion (e.g., evaporate) appreciably during
the application, and should not alter the
permeability properties ofthe skin. Ifsolid
material applications are required, the test
material should be applied in a manner
consistent with the anticipated human
exposure. Ifnecessary, pilot or in vitro skin
penetration studies should be conducted to
determine ifsolid material will absorb into
the skin. In the application of cutaneous
doses, dose per unit area should be the
major consideration. The criteria for select-
ing surface area also should consider the
analytic sensitivity ofavailable methods of
detection. The surface area for application
should be appropriately determined and
reported; it is typically in the range of 5 to
10 cm2 for the rat. For irritating chemicals,
a vehicle may be introduced to dilute the
dose applied to reduce irritation.
b) Determination of the extent of
absorption following cutaneous application.
For purposes ofdetermining the extent
ofabsorption oftest chemical, mass balance
studies are sufficient. When more detailed
pharmacokinetic data are required, it is rec-
ommended that the systemic dose over time
be determined by measuring the concentra-
tion of unmetabolized chemical in the
plasma. The fraction ofdose absorbed can
be estimated from AUC measurements
derived from administration of the same
dose by both the iv and dermal routes and
can be compared with the absorbed dose
from the mass balance studies
c) What is the most effective way to
handle removal (wash-off) ofmaterial from
the application site?
The discussants recognized that a pur-
pose ofthe dermal washing efficiency study
is to determine the efficiency ofwashing by
soap and water at the end of a work day.
The discussion group recommended that
washing not be done using a solvent. The
use ofanesthesia for the washoffprocedure
in animals, while not completely relevant
to either toxicity study exposure regimens
or to estimations ofhuman exposure, may
be warranted for the purpose ofdetermin-
ing quantitative recovery and to minimize
stress to the test animal. The use, of anes-
thesia should generally be left to the discre-
tion of the investigator and to ensure that
humane procedures are employed.
d) At study termination, what is the
most effective procedure for recovery of
test material from the application site?
The discussants agreed that removal of
the treated skin area from the test animal at
the time ofsacrifice, followed by analysis of
a piece ofthis skin for residual radioactiv-
ity, was an appropriate method to deter-
mine the amount ofchemical remaining at
the site ofapplication.
e) What are the best means ofpreparing
the surface area and applying the dose, and
what types of containments or coverings
should be used to protect the dose site?
The decision to occlude the exposure
site should be based on the exposure sce-
nario being modeled. It is recognized that
occlusion will generally increase and
enhance dermal absorption. Pilot studies
should be conducted to determine the
interaction of occlusive and containment
materials with the test substance. The dis-
cussants further recommended that the
exposure site be washed no sooner than 6
hr after application ofthe test substance. It
also was agreed that it may not be practical
for volatile substances to keep the test sub-
stance on the skin for a minimum of6 hr.
The discussants could not reach a consen-
sus regarding the occlusion of volatile
materials and further identified that there is
currently no generally recognized proce-
dure for studying skin absorption for
volatile chemicals. In such cases, in vitro
methods may be useful in estimating skin
penetration versus evaporation.
f) Problems enountered and effective
resolutions of low radioactivity recoveries
from dermal study segments.
While recoveries of >90% are desirable
for material balance studies, in dermal
studies, lower recoveries are often obtained
and the causes for the lower recovery are
not always understood or apparent. The
acceptability of lower dermal recoveries
should be considered on a case-by-case
basis. These problems are generally related
to difficulties in recovering radioactivity
from containment devices and materials or
omission ofvolatile organic chemical traps
or both. Also, it was recognized that this
latter question may be resolved by conduct-
ing a probe study prior to the definitive
study.
AdditionalDiscussion-Use ofProbe
Studies. These additional recommenda-
tions were made to be consistent with the
concept of a minimum data set (tier 1). It
was agreed that probe studies can be used
for a) the establishment of an appropriate
experimental design (e.g., intervals after
dose application for blood and excreta sam-
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pling); b) defining the excretion pharmaco-
kinetics and appropriate study duration; c)
evaluating radioactive dose recovery proce-
dures and use ofvolatile and CO2 traps; a)
collecting blood and urine samples for
analytic method development; and
e) conducting in vitro skin studies to answer
questions regarding volatile chemical appli-
cations (e.g., evaporation versus penetra-
tion), vehicle effects on absorption, and
penetration ofhuman skin preparations.
Most ofthe discussants also agreed that
one sex (preferably male) could be used. It
was generally agreed that no substantial sex
difference exists in the area of dermal
absorption for the majority of chemicals




For several reasons, most notable ofwhich
is the feasibility of monitoring, dose and
exposure should be specified in terms of
chamber concentration rather than
deposited or delivered dose. Chamber con-
centration ofthe test agent should always be
measured and in the case ofaerosols, parti-
cle size distribution of the test substance
should be characterized. The plasma AUC
for the parent compound should be used as
a surrogate for the delivered dose. An iv
dose study (if feasible) needs to be con-
ducted to provide a reference AUC value
for the parent compound. The discussion
group agreed that plethysmography should
not be routinely required. The work group
suggested that highly irritating doses oftest
substances that might alter the breathing
patterns are properly considered to produce
overt toxicity and are thus doses that are
more than minimally toxic. With regard to
explosive organic vapors, for safety reasons
the test doses should not exceed 50% ofthe
lower explosive limit (LEL). Pulmonary
clearance ofdeposited particulates is not an
issue for minimal PK testing; however, it
should be considered for longer term (14-
and 90-day) tests.
The group strongly endorsed pilot stud-
ies to aid in the design of blood sampling
schedules. They agreed that blood sam-
pling is important to carry out during
exposure. After discussing the difficulties of
multiple sampling during any test (because
of reduced blood volume considerations),
the discussion group recommended that
PK studies should be conducted on adult
rats up to 16 weeks old. Because of the
difficulty of simultaneously sampling
breath, urine, feces, and blood, the group
agreed that two test groups are needed-
one to study blood concentrations, the
other to study excreted material (in breath,
urine, feces). Two test groups may not be
needed if pilot studies indicate minimal
parent compound and metabolite exhala-
tion.
Methods to maintain volatile com-
pounds in urine and feces were discussed,
and it was concluded that cryogenic trap-
ping techniques are available and should be
used. Measuring volatile compounds in
blood during exposure and in blood, urine,
feces and expired air collected postexposure
would provide sufficient data unless special
circumstances dictate otherwise. Collection
ofurine and feces during exposure was not
considered necessary.
Study Design Considerations. With
regard to whole-body versus head-only sys-
tems, dermal absorption and preening
complicate the pharmacokinetics profile
from animals exposed in whole-body
chambers. The group, therefore, recom-
mended using head-only exposures.
However, it was recognized that closed-loop
recirculating systems can provide useful
information under certain circumstances.
The group agreed that 6-hr exposures
are a good standard for PK evaluation. A
minimum oftwo inhalation exposure con-
centrations are necessary to detect dispro-
portionate changes in the pharmacokinetic
profile. The group suggested that the mul-
tiple exposure studies could be ofthe seven
consecutive daily exposure format or alter-
native schedules of repeat exposure ifade-
quately justified. The group concluded that
some flexibility in criteria for cessation ofa
test should be available. The criterion of
90% elimination of the administered dose
is difficult to ascertain in inhalation
studies. The group discussed the need for
determining the absorbed dose immedi-
ately following the exposure. They con-
cluded that while this was advisable, its
applicability should be determined on a
case-by-case basis.
Concerning aerosols, radiolabels, and
insoluble particles, the group concluded that
using an iv dose should not be a routine part
ofan inhalation PK study for insoluble par-
ticles. However, an iv dose should be used
routinely for soluble aerosols. Aerosols, espe-
cially insoluble and aerosol-vapor mixtures,
will often require compound- or mixture-
specific consideration.
Additional Considerations. The
specific times for collecting blood and exc-
reta should be determined by pilot studies.
Sampling ofdifferent levels ofthe respira-
tory tract was discussed at length but was
not recommended for typical PK studies.
Mixtures raise extremely complex ques-
tions, and they should be considered on a
case-by-case basis.
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